XIGDUO – fixed combination of the active ingredients dapagliflozin and metformin

Česká verzia

Authors: Tomáš Edelsberger
Authors place of work: Diabetologická ambulance Krnov
Published in the journal: Vnitř Lék 2016; 62(3): 199-201
Category: Reviews

Summary

Fixed dose combination of two different drugs in the same or related indications are successfully used in various medical fields including diabetology. This article deals with the combination therapy comprising metformin and dapagliflozin in a single preparation, molecules affecting different pathophysiological mechanisms of type 2 diabetes, particularly insulin resistance and increased glucose reabsorption in the kidney. Most patients with type 2 diabetes does not achieve target glycemic control when treated with single antidiabetics and need for proper control of diabetes combination of several different drugs. Using the fixed combination leads to improved patient’s adherence and utilization of the full therapeutic potential of selected drugs.

Key words:
combination therapy – diabetes mellitus – fixed-dose combinations – oral antidiabetics – SGLT2 inhibitors

Zdroje

1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4):773–795.

2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(10): 1925–1938.

3. Han S, Iglay K, Davies MJ et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dualtherapy ofantihyperglycemic regimens: a meta-analysis. Curr Med Res Opin 2012; 28(6): 969–977.

4. Bell DSH. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013; 15(4): 291–300.

5. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16(5): 457–466.

6. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic controlwithmetformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34(9): 2015–2022..

7. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review andmetaanalysis. Ann Intern Med 2013; 159(4): 262–274.

8. Henry RR, Murray AV, Marmolejo MH et al, Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66(5): 446–456.

9. SPC XIGDUO. Dostupné z WWW: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002672/WC500161033.pdf.